Viruses, Vol. 14, Pages 1459: Fulminant Adenoviral-Induced Hepatitis in Immunosuppressed Patients
hmid Tobias Lahmer Human adenovirus (HAdV) can often lead to fulminant hepatitis in immunocompromised patients, mostly after reactivation of HAdV. Different risk factors, e.g., transplantation and chemotherapy, increase the risk of developing a HAdV hepatitis. We retrospectively analyzed three patients who showed the characteristics of a HAdV hepatitis observed in disseminated disease. In addition to PCR, diagnosis could be proven by pathology, CT scan, and markedly elevated transaminases. All patients had a hemato-oncologic underlying disease. Two had received a stem-cell transplant, and one was under chemotherapy i...
Source: Viruses - July 1, 2022 Category: Virology Authors: Juliane Kager Jochen Schneider Sebastian Rasch Peter Herhaus Mareike Verbeek Carolin Mogler Albert Heim Gert Fr ösner Dieter Hoffmann Roland M. Schmid Tobias Lahmer Tags: Case Report Source Type: research

65-Year-Old Man With Weight Loss and Dyspnea on Exertion
A 65-year-old man, a nonsmoker, presented to the hospital in mid-February 2021 with a 30- to 40-lb weight loss over 2 to 3 months and profound fatigue. He also endorsed dyspnea on exertion, a productive cough, and profuse watery diarrhea for several days. Clinical comorbidities included a diagnosis of Mantle cell lymphoma (MCL) in remission after treatment with chemotherapy (cyclophosphamide, vincristine, doxorubicin), autologous stem cell transplant (ASCT) in May 2019 and maintenance rituximab every 8 weeks, hypogammaglobinemia, hypertension on lisinopril, type 2 diabetes mellitus (T2DM) on metformin, and coronary artery ...
Source: Mayo Clinic Proceedings - July 1, 2022 Category: Internal Medicine Authors: Nathan Nesbitt, Max J. Martin, Patricio Escalante Tags: Residents ’ clinic Source Type: research

Real-world Clinical Outcomes of First-Line Ibrutinib or Chemoimmunotherapy in Patients with Chronic Lymphocytic Leukemia by Risk Status
ConclusionThis study found that first-line single-agent ibrutinib therapy was associated with significantly longer TTNT than CIT regimens in real-world patients with high-risk CLL. The results support the use of ibrutinib in high-risk patients.Infographic (Source: Advances in Therapy)
Source: Advances in Therapy - June 30, 2022 Category: Drugs & Pharmacology Source Type: research

Successful Management of Severe Hyperhaemolysis with Combined Tocilizumab and Rituximab in Non-Transfusion-Dependent Thalassaemia: A Case Report
Conclusion: Tocilizumab can be effectively combined with rituximab to stop hyperhaemolytic episode refractory to first-line treatment when a prompt response is needed.Transfus Med Hemother (Source: Transfusion Medicine and Hemotherapy)
Source: Transfusion Medicine and Hemotherapy - June 30, 2022 Category: Hematology Source Type: research

18F-FDG PET Improves Baseline Clinical Predictors of Response in Diffuse Large B-Cell Lymphoma: The HOVON-84 Study
Conclusion: In this study on diffuse large B-cell lymphoma, I-PET after 4 cycles of R(R)-CHOP14 added predictive value to aaIPI for 2-y PFS, and both were independent response biomarkers in a multivariable Cox model. We externally validated that SUVmax outperformed DS in 2-y PFS prediction. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - June 30, 2022 Category: Nuclear Medicine Authors: Burggraaff, C. N., Eertink, J. J., Lugtenburg, P. J., Hoekstra, O. S., Arens, A. I. J., de Keizer, B., Heymans, M. W., van der Holt, B., Wiegers, S. E., Pieplenbosch, S., Boellaard, R., de Vet, H. C. W., Zijlstra, J. M., on behalf of the HOVON Imaging Wor Tags: Clinical Investigations Source Type: research

Cancers, Vol. 14, Pages 3229: Tumor Microenvironment and Immunotherapy-Based Approaches in Mantle Cell Lymphoma
ne Sarkozy Mantle cell lymphoma (MCL) is an aggressive B-cell non-Hodgkin lymphoma (NHL) characterized by the translocation t(11;14) (q13;q32) and a poor response to rituximab–anthracycline-based chemotherapy. High-dose cytarabine-based regimens offer a durable response, but an important number of MCL patients are not eligible for intensive treatment and are ideal candidates for novel targeted therapies (such as BTK, proteasome or BCL2 inhibitors, Immunomodulatory Drugs (IMiDs), bispecific antibodies, or CAR-T cell therapy). On the bench side, several studies aiming to integrate the tumor within its ecosy...
Source: Cancers - June 30, 2022 Category: Cancer & Oncology Authors: Khalil Saleh Morgane Cheminant David Chiron Barbara Burroni Vincent Ribrag Cl émentine Sarkozy Tags: Review Source Type: research

Rituximab Therapy for Mucous Membrane Pemphigoid: A Retrospective Monocentric Study With Long-Term Follow-Up in 109 Patients
Mucous membrane pemphigoid (MMP) is a heterogeneous group of rare, chronic, subepithelial autoimmune blistering diseases (AIBDs) with predominant involvement of mucous membranes that can be sight-threatening and life-threatening. Rituximab (RTX) has demonstrated its efficacy in severe MMP refractory to conventional immunosuppressants in small series that differed in RTX scheme, concomitant therapies, and outcome definitions. In a meta-analysis involving 112 patients with MMP treated with RTX, complete remission (CR) was reported in 70.5% of cases. Herein, we report the largest retrospective monocentric study on RTX efficac...
Source: Frontiers in Immunology - June 30, 2022 Category: Allergy & Immunology Source Type: research

KIR2DS2 Expression Identifies NK Cells With Enhanced Anticancer Activity
This study provides evidence that KIR2DS2 marks a population of NK cells primed for anticancer activity and indicates that KIR2DS2 is an attractive target for NK-based therapeutic strategies.PMID:35768150 | DOI:10.4049/jimmunol.2101139 (Source: Journal of Immunology)
Source: Journal of Immunology - June 29, 2022 Category: Allergy & Immunology Authors: Matthew D Blunt Andres Vallejo Pulido Jack G Fisher Lara V Graham Amber D P Doyle Rebecca Fulton Matthew J Carter Marta Polak Peter W M Johnson Mark S Cragg Francesco Forconi Salim I Khakoo Source Type: research

Clinical observation of different doses of rituximab for the treatment of severe pemphigus: A single-center prospective cohort study
(Source: Journal of the American Academy of Dermatology)
Source: Journal of the American Academy of Dermatology - June 29, 2022 Category: Dermatology Authors: Jiao Zhang, Xueyi Huang, Zeqiao Zhang, Peizhen Zhao, Wenjing Chen, Yunsheng Liang, Hongfang Liu, Zemin Zhong, Yongfeng Chen Source Type: research

Treatment Outcomes and Roles of Transplantation and Maintenance Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma: Results From Large Real-World Cohorts
CONCLUSION: In this large cohort of patients treated primarily in the US community setting, only one in four young patients received cytarabine or ASCT consolidation, suggesting the need to develop treatments that can be delivered effectively in routine clinical practice. Together with the validation cohort, data support future clinical trials exploring regimens without ASCT consolidation in young patients, whereas MR should be considered for patients after 1L BR and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.PMID:35763708 | DOI:10.1200/JCO.21.02698 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - June 28, 2022 Category: Cancer & Oncology Authors: Peter Martin Jonathon B Cohen Michael Wang Anita Kumar Brian Hill Diego Villa Jeffrey M Switchenko Brad Kahl Kami Maddocks Natalie S Grover Keqin Qi Lori Parisi Katherine Daly Angeline Zhu Gilles Salles Source Type: research

Treatment Outcomes and Roles of Transplantation and Maintenance Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma: Results From Large Real-World Cohorts
CONCLUSION: In this large cohort of patients treated primarily in the US community setting, only one in four young patients received cytarabine or ASCT consolidation, suggesting the need to develop treatments that can be delivered effectively in routine clinical practice. Together with the validation cohort, data support future clinical trials exploring regimens without ASCT consolidation in young patients, whereas MR should be considered for patients after 1L BR and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.PMID:35763708 | DOI:10.1200/JCO.21.02698 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - June 28, 2022 Category: Cancer & Oncology Authors: Peter Martin Jonathon B Cohen Michael Wang Anita Kumar Brian Hill Diego Villa Jeffrey M Switchenko Brad Kahl Kami Maddocks Natalie S Grover Keqin Qi Lori Parisi Katherine Daly Angeline Zhu Gilles Salles Source Type: research

B-cell lymphoma-associated hemophagocytic lymphohistiocytosis: A case report
Oncol Lett. 2022 Jun 7;24(2):246. doi: 10.3892/ol.2022.13365. eCollection 2022 Aug.ABSTRACTHemophagocytic lymphohistiocytosis (HLH) is a life-threatening condition characterized by an exaggerated but dysregulated immune response resulting in hyperinflammation, with a potential for progression to multiple organ dysfunction and failure. Infectious diseases, inflammatory disorders, malignancies and immunodeficiency syndromes are known triggers of HLH in adults. The present study reported the case of a middle-aged man with HLH triggered by B-cell lymphoma who was successfully treated with dexamethasone; etoposide, prednisone, ...
Source: Oncology Letters - June 28, 2022 Category: Cancer & Oncology Authors: Ademola S Ojo Joseph Asemota Somtochukwu Ojukwu Ahmad Rajeh Amina Bot Caitlyn J Smith Katsiaryna Laziuk Mohammed Saleh Source Type: research

Prognostic value of circulating lymphocyte subsets in primary central nervous system lymphoma
ConclusionLIP at baseline may predict refractory disease and exhibits a prognostic value in CNS-DLBCL patients. (Source: Journal of Neuro-Oncology)
Source: Journal of Neuro-Oncology - June 28, 2022 Category: Cancer & Oncology Source Type: research

Retrospective Analysis of the Efficacy and Tolerability of Gemcitabine-based Chemotherapy in Relapsed/Refractory Lymphoma Patients Not Eligible for Stem Cell Transplant
Gemcitabine-based regimens are effective salvage therapy for RR lymphoma patients eligible for ASCT, but there is limited data in transplant-ineligible (TIE) patients. Here, we present a retrospective analysis on the outcome of TIE adult patients with RR lymphoma treated with gemcitabine, cisplatin or carboplatin and dexamethasone (GDP/GDCarboP) +/- rituximab regimen in our center. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - June 28, 2022 Category: Hematology Authors: May Chiu, Samuel Hague, Anna Elinder-Camburn, Eileen Merriman, Henry Chan Tags: Original Study Source Type: research